22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Allogene Therapeutics, Inc. › 2024-2025

Allogene Therapeutics, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Allogene Therapeutics, Inc.’s Form 8-K, filed June 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 141Asset managers, any item
  • 824Fund votes
  • June 18, 2025Meeting date

Results at a glance

Meeting of June 18, 2025: 5 items on Allogene Therapeutics, Inc.’s Form 8-K, filed June 23, 2025: 3 elected · 2 approved.

Dissent

Notable dissent: 1 director (16.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Allogene Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Allogene Therapeutics, Inc.

These tallies are Allogene Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Allogene Therapeutics, Inc. — official shareholder meeting results, meeting held June 18, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Elizabeth Barrett 131,435,760---- 25,929,65433,512,034 84%Elected—
Elect Director: Arie Belldegrun, M.D. 150,891,245---- 6,474,16933,512,034 96%Elected—
Elect Director: David Chang, M.D., Ph.D. 153,721,017---- 3,644,39733,512,034 98%Elected—
2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers 139,947,86814,233,3093,184,237 --33,512,034 91%Approved—
3. Ratification of the Selection of Independent Registered Public Accounting Firm 190,111,256414,604351,588 --0 99.8%Approved—

Source: Allogene Therapeutics, Inc., Form 8-K, filed with the SEC on June 23, 2025 — read the filing on EDGAR.

How asset managers voted at the Allogene Therapeutics, Inc. 2024-2025 meeting

141 asset managers disclosed a vote on at least one Allogene Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Arie Belldegrun, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 150,891,245WITHHELD: 6,474,169
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Directors: Arie Belldegrun, M.D.

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 150,891,245 for, 6,474,169 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 26,989,897 for, 1,883,941 withheld.

FOR
FOR: 26,989,897WITHHOLD: 1,883,941
Largest asset managers voting on “Election of Directors: Arie Belldegrun, M.D.” at Allogene Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group12,265,3300 00For
Vanguard5,033,7800 00For
T. Rowe Price3,096,5720 00For
BlackRock2,062,7160 00For
PRIMECAP Odyssey Funds1,785,2700 00For
Aberdeen00 0867,250Withhold
JPMorgan682,9590 00For
Equitable214,7150 0222,038Mixed
Charles Schwab428,8180 00For
Columbia Threadneedle273,8750 00For
Fidelity263,2400 00For
Lincoln Financial137,5360 0111,015Mixed
Global X241,5640 00For
Delaware/Macquarie00 0146,779Withhold
Zacks Trust137,1610 00For
State Street450 0120,405Withhold
AIG/SunAmerica00 096,500Withhold
John Hancock81,3760 010,737Mixed
Northern Trust76,8180 00For
Pacific Life68,9120 00For
ETF Series Solutions00 068,858Withhold
ETFis Series Trust I00 060,814Withhold
Bridge Builder Trust57,9840 00For
Blackstone Alternative Investment Funds00 044,900Withhold
RBB FUND, INC.33,6210 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Elect Director: David Chang, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 153,721,017WITHHELD: 3,644,397
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Directors: David Chang, M.D., Ph.D.

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: David Chang, M.D., Ph.D.”): 153,721,017 for, 3,644,397 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 28,301,714 for, 572,124 withheld.

FOR
FOR: 28,301,714WITHHOLD: 572,124
Largest asset managers voting on “Election of Directors: David Chang, M.D., Ph.D.” at Allogene Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group12,265,3300 00For
Vanguard5,033,7800 00For
T. Rowe Price3,096,5720 00For
BlackRock2,062,7160 00For
PRIMECAP Odyssey Funds1,785,2700 00For
Aberdeen867,2500 00For
JPMorgan682,9590 00For
Equitable436,7530 00For
Charles Schwab428,8180 00For
Columbia Threadneedle273,8750 00For
Fidelity263,2400 00For
Lincoln Financial231,3360 017,215Mixed
Global X241,5640 00For
Delaware/Macquarie00 0146,779Withhold
Zacks Trust137,1610 00For
State Street120,4200 030For
AIG/SunAmerica00 096,500Withhold
John Hancock81,3760 010,737Mixed
Northern Trust76,8180 00For
Pacific Life68,9120 00For
ETF Series Solutions00 068,858Withhold
ETFis Series Trust I00 060,814Withhold
Bridge Builder Trust57,9840 00For
Blackstone Alternative Investment Funds00 044,900Withhold
RBB FUND, INC.33,6210 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Elect Director: Elizabeth Barrett

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD
FOR: 131,435,760WITHHELD: 25,929,654
Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: Election of Directors: Elizabeth Barrett

Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 131,435,760 for, 25,929,654 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 11,152,293 for, 17,721,545 withheld.

FORWITHHOLD
FOR: 11,152,293WITHHOLD: 17,721,545
Largest asset managers voting on “Election of Directors: Elizabeth Barrett” at Allogene Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group00 012,265,330Withhold
Vanguard2,964,5700 02,069,210Mixed
T. Rowe Price3,096,5720 00For
BlackRock1,681,8910 0380,825Mixed
PRIMECAP Odyssey Funds1,785,2700 00For
Aberdeen00 0867,250Withhold
JPMorgan682,9590 00For
Equitable55,5590 0381,194Mixed
Charles Schwab00 0428,818Withhold
Columbia Threadneedle273,8750 00For
Fidelity217,2180 046,022Mixed
Lincoln Financial137,5360 0111,015Mixed
Global X00 0241,564Withhold
Delaware/Macquarie00 0146,779Withhold
Zacks Trust137,1610 00For
State Street450 0120,405Withhold
AIG/SunAmerica00 096,500Withhold
John Hancock81,3760 010,737Mixed
Northern Trust00 076,818Withhold
Pacific Life00 068,912Withhold
ETF Series Solutions00 068,858Withhold
ETFis Series Trust I00 060,814Withhold
Bridge Builder Trust00 057,984Withhold
Blackstone Alternative Investment Funds00 044,900Withhold
RBB FUND, INC.33,6210 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

91% Approved · of votes cast

FOR 91%
FOR: 139,947,868AGAINST: 14,233,309

Prior year: 88.0% for (June 5, 2024 meeting) ▲ 2.8 pts

Details: description as filed, official tally, votes by 141 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Allogene Therapeutics, Inc.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 139,947,868 for, 14,233,309 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Allogene Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group012,265,330 00Against
Vanguard5,033,7800 00For
T. Rowe Price3,096,5720 00For
BlackRock2,062,7160 00For
PRIMECAP Odyssey Funds1,785,2700 00For
Aberdeen867,2500 00For
JPMorgan682,9590 00For
Equitable436,7530 00For
Charles Schwab428,8180 00For
Columbia Threadneedle273,8750 00For
Fidelity263,2400 00For
Lincoln Financial248,5510 00For
Global X241,5640 00For
Delaware/Macquarie146,7790 00For
Zacks Trust137,1610 00For
State Street120,4419 00For
AIG/SunAmerica96,5000 00For
John Hancock92,1130 00For
Northern Trust76,8180 00For
Pacific Life68,9120 00For
ETF Series Solutions68,8580 00For
ETFis Series Trust I60,8140 00For
Bridge Builder Trust57,9840 00For
Blackstone Alternative Investment Funds44,9000 00For
RBB FUND, INC.33,6210 00For

Fund voting reports, all 46 managers: 16,588,976 for, 12,284,862 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 109 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Allogene Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group012,265,360 00Against
Lynx1 Capital Management LP11,057,0090 00For
Citadel9,227,6020 00For
BlackRock5,465,783115,146 00For
PRIMECAP MANAGEMENT CO/CA/4,879,1400 00For
T. Rowe Price4,170,0690 00For
Frazier Life Sciences Management, L.P.3,868,7500 00For
Goldman Sachs3,785,16853,987 00For
Woodline Partners LP3,709,3570 00For
Foresite Capital Management VI LLC3,448,2750 00For
Wildcat Capital Management, LLC00 2,920,7870Abstain
JPMorgan2,890,4040 00For
Vida Ventures Advisors, LLC1,798,1630 00For
DAFNA Capital Management LLC1,380,1180 00For
State Street1,361,1549 00For
GILEAD SCIENCES, INC.1,156,6890 00For
Aberdeen867,2500 00For
BBR PARTNERS, LLC798,8990 00For
TPG GP A, LLC675,0000 00For
Northern Trust572,3870 00For
Charles Schwab428,8410 00For
Cerity Partners LLC414,4990 00For
ZACKS INVESTMENT MANAGEMENT319,9500 00For
Mitsubishi UFJ Asset Management Co., Ltd.267,3360 00For
Moloney Securities Asset Management, LLC265,0000 00For

Institutional-manager reports, all 109 managers: 65,175,172 for, 12,535,929 against, 2,920,787 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

99.8% Approved · of votes cast

FOR 99.8%
FOR: 190,111,256AGAINST: 414,604

Prior year: 99.1% for (June 5, 2024 meeting) ▲ 0.7 pts

Details: description as filed, official tally, votes by 47 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

Allogene Therapeutics, Inc.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 190,111,256 for, 414,604 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 28,873,838 for.

FOR
FOR: 28,873,838
Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independe” at Allogene Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group12,265,3300 00For
Vanguard5,033,7800 00For
T. Rowe Price3,096,5720 00For
BlackRock2,062,7160 00For
PRIMECAP Odyssey Funds1,785,2700 00For
Aberdeen867,2500 00For
JPMorgan682,9590 00For
Equitable436,7530 00For
Charles Schwab428,8180 00For
Columbia Threadneedle273,8750 00For
Fidelity263,2400 00For
Lincoln Financial248,5510 00For
Global X241,5640 00For
Delaware/Macquarie146,7790 00For
Zacks Trust137,1610 00For
State Street120,4500 00For
AIG/SunAmerica96,5000 00For
John Hancock92,1130 00For
Northern Trust76,8180 00For
Pacific Life68,9120 00For
ETF Series Solutions68,8580 00For
ETFis Series Trust I60,8140 00For
Bridge Builder Trust57,9840 00For
Blackstone Alternative Investment Funds44,9000 00For
RBB FUND, INC.33,6210 00For

Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).

Largest Allogene Therapeutics, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 218,598,262 shares outstanding at the time of that meeting.

Fund voting reports: top Allogene Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 5.61%
2Vanguard 2.30%
3T. Rowe Price 1.42%
4BlackRock 0.94%
5PRIMECAP Odyssey Funds 0.82%
6Aberdeen 0.40%
7JPMorgan 0.31%
8Equitable 0.20%
9Charles Schwab 0.20%
10Columbia Threadneedle 0.13%
Institutional-manager reports: top Allogene Therapeutics, Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 5.61%
2Lynx1 Capital Management LP 5.06%
3Citadel 4.22%
4BlackRock 2.55%
5PRIMECAP MANAGEMENT CO/CA/ 2.23%
6T. Rowe Price 1.91%
7Frazier Life Sciences Management, L.P. 1.77%
8Goldman Sachs 1.76%
9Woodline Partners LP 1.70%
10Foresite Capital Management VI LLC 1.58%

Reported Allogene Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Allogene Therapeutics, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Pfizer Inc.22,032,040 10.08%Schedule 13D, filed February 13, 2026
TPG GP A, LLC18,716,306 8.56%Proxy statement (DEF 14A), proxy filed April 30, 2025
BlackRock17,932,906 8.20%Form 13F, quarter ended March 31, 2025
Arie Belldegrun, M.D.13,466,383 6.16%Schedule 13G, filed May 13, 2026
David D. Chang, M.D., Ph.D.12,297,354 5.63%Schedule 13G, filed May 13, 2026
David Chang, M.D., Ph.D.11,043,100 5.05%Proxy statement (DEF 14A), proxy filed April 30, 2025
Citadel Advisors10,302,629 4.71%Form 13F, quarter ended March 31, 2025
Vanguard Group8,067,553 3.69%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)7,394,162 3.38%Form 13F, quarter ended March 31, 2025
Kenneth Griffin6,855,120 3.14%Schedule 13G, filed May 15, 2026

Percentages above are of 218,598,262 shares outstanding, as reported by Allogene Therapeutics, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Allogene Therapeutics, Inc.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 141 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 824 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Allogene Therapeutics, Inc.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Allogene Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 23, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Allogene Therapeutics, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Allogene Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Allogene Therapeutics (ALLO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/allogene-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.